Research Article

Catalyst-Free Synthesis of Highly Biologically Active 5-Arylidene Rhodanine and 2,4-Thiazolidinedione Derivatives Using Aldonitrones in Polyethylene Glycol

Dhruva Kumar, Suresh Narwal, and Jagir S. Sandhu

Department of Chemistry, Punjabi University, Patiala, Punjab 147002, India

Correspondence should be addressed to Jagir S. Sandhu; j.sandhu2002@yahoo.com

Received 11 December 2012; Accepted 14 January 2013

A green, efficient synthesis of 5-arylidene rhodanine and 2,4-thiazolidinedione derivatives without using any external catalyst in polyethylene glycol (PEG) at 80°C has been described. Reaction procedure is very simple, short, and obtained yields are very high.

1. Introduction

Rhodanines and thiazolidinediones both are privileged class of molecule, and they show large number of biological activities. The most significant position of these molecules seems to be as they are as a subset of commercially employed noninsulin-dependent diabetes mellitus (NIDDM), insulin sensitizing agents (Figure 1) such as epalrestat, cigitazone, AD-5061, pioglitazone, rosiglitazone, and so forth.

Furthermore, rhodanine derivatives possess anticonvulsant, antibacterial, antiviral, and antidiabetic activities [1–3] Some of rhodanine-based derivatives act as hepatitis C virus (HCV) protease inhibitor [4], uridine diphospho-N-acetylmuramate/L-alanine ligase inhibitor [5], aldose reductase [6], β-lactamase [7], and JNK-stimulating phosphatase-1 (JSP-1) [8], while some of its derivatives are used for the analysis of certain noble metal ions [9]. Therefore, the synthesis of rhodanine derivatives currently is of much importance and a variety of methods and catalysts have been used [10–12].

Unlike rhodanine, 2,4-thiazolidinedione derivatives also have remarkable biological activities like antidiabetic [13], antibacterial [14], antifungal [15], antiproliferative effect on vascular smooth muscle [16], aldose reductase inhibitors [17], 15-hydroxyprostaglandin dehydrogenase inhibitors [18] instead of these biological activities 5-benzylidene-thiazolidine-2,4-dione derivatives act as inhibitors of MurD ligase [19]. In the literature several methods have been reported to synthesize these privileged molecules [20–24]. Therefore, significant biological activities prompt us to synthesize thiazolidine derivatives.

Nitrones (imine oxides) are reputed as 1,3-dipoles and are extensively explored for the synthesis of five-membered heterocycles by combining them with several types of multiple bonds [25–27]. Apart from this major utility their general chemistry is little studied. [27] There are few reports of successful 1,3-addition of nitrones [28,29]. Yousif et al. reported reactions of heterocyclic N-oxides under acidic conditions and obtained only condensed products [30]. In contrast, their counterpart imines are extensively explored to expose their utility as aldehyde equivalent [31–33]. Present protocol is the environment benign synthesis of 5-arylidene rhodanine and 2,4-thiazolidinedione derivatives using aldonitrones in polyethylene glycol (PEG). The reaction proceeds via addition-elimination way and afforded the desire products in very good to excellent yield (Scheme 1).

2. Results and Discussion

First of all, a series of nitrones was prepared using a variety of aldehyde and hydroxyl amine as per already reported method [34]. A mixture of freshly prepared N-phenyl-N-phenylmethylidenamine oxide (10 mmol) 1a and rhodanine
(10 mmol) 2a was stirred at 80 °C in polyethylene glycol (PEG) for 20 min to afford corresponding arylidene rhodanine 3a via addition-elimination process.

To check the effect of the solvent, a set of reactions was performed using different solvents such as MeOH, EtOH, H2O, THF, PEG, DMF, and so forth and in absence of solvent. Conclusively, in case of PEG best results were obtained with high yields in minimum reduced time. Keeping optimized reaction conditions, a variety of aldehydes with rhodanine/2,4-thiazolidinedione were reacted to afford 5-arylidene rhodanines 3a–g and 5-arylidene-2,4-thiazolidinediones 3h–n with excellent yields (Table 1).

Active methylene compounds 2a–b afforded the Knoevenagel products 3a–n selectively with exo-double bond without the formation of other side-products/bis-products as shown in Scheme 2 via addition-elimination process. Electron withdrawing and donating groups on aromatic N-oxides showed slightly diversion in rate of reaction and yields; that is, electron withdrawing group containing aromatic N-oxides afforded arylidene compounds with better yields in shorter reaction time (Table 1).

Next, the recyclability of the solvent was studied by using 1a and 2a as the model substrates. We observed that PEG could be recovered by under vacuum filtration of products obtained on cooling. PEG recovered as filtrate and was successfully recycled and reused for five runs.

As far as mechanism is concerned, reaction proceeds via nucleophilic addition of 2 on 1 with subsequent elimination of amine part of aromatic N-oxides to afford arylidene products 3 (Scheme 2).

**Figure 1:** Clinically used molecules having 5-arylidene rhodanines and 2,4-thiazolidinediones.

**Scheme 1:** Synthesis of 5-arylidene thiazolidinediones.

**Table 1:** Synthesis of 5-arylidene rhodanine and 2,4-thiazolidinedione derivatives using aldonitrones in polyethylene glycol (PEG).

| Entry | X   | Y   | Product | Time (min) | Yield (%) | Melting point (°C) reference |
|-------|-----|-----|---------|------------|-----------|-----------------------------|
| 1     | H   | S   | 3a      | 20         | 85        | 202-203 [11]                |
| 2     | 4-Cl| S   | 3b      | 20         | 93        | 230-232 [11]                |
| 3     | 4-Br| S   | 3c      | 20         | 89        | 229-230 [3]                 |
| 4     | 4-NO2| S | 3d      | 25         | 94        | 254-255 [11]                |
| 5     | 4-CH3| S | 3e      | 30         | 78        | 224-225 [11]                |
| 6     | 4-CH3| O | 3f      | 30         | 83        | 250-251 [11]                |
| 7     | 4-OH | S  | 3g      | 30         | 79        | 184-185 [35]                |
| 8     | H   | O   | 3h      | 25         | 92        | 240-241 [36]                |
| 9     | 3-Cl| O   | 3i      | 25         | 88        | 270-271 [36]                |
| 10    | 4-Cl| O   | 3j      | 25         | 85        | 224-225 [37]                |
| 11    | 4-NO2| O | 3k      | 25         | 75        | 260-262 [37]                |
| 12    | 4-CH3| O | 3l      | 25         | 86        | 224-225 [37]                |
| 13    | 4-CH3| O | 3m      | 35         | 88        | 234-235 [36]                |
| 14    | 4-OH | O  | 3n      | 35         | 90        | 280-281 [36]                |

*Reaction conditions: 1a–h (10 mmol), 2a–b (10 mmol), and polyethylene glycol (PEG) 5 mL were heated at 80 °C on magnetic stirrer. The products were characterized by spectral techniques like IR, 1H NMR. Isolated yields after recrystallization.
3. Conclusion

In summary, the present protocol is an efficient and environmentally benign procedure for the synthesis of drug intermediate 5-arylidene rhodanine and 2,4-thiazolidinedione derivatives using aldonitrones in polyethylene glycol (PEG) via simple addition-elimination process. Present protocol does not need any external catalyst, and it is applicable on a variety of nitrones. This method produces good to excellent yields in shorter reaction time, and it seems that reaction is autocatalyzed because eliminating part of nitrone acts as catalyst.

4. Experimental Section

4.1. General. Reagent-grade chemicals were purchased from a commercial source and used without further purification. Yields refer to the yield of the isolated products. Melting points were determined in open capillaries in paraffin bath and are uncorrected. Infrared (IR) spectra were recorded in KBr discs on a Perkin-Elmer 240C analyzer. 1H NMR spectra were recorded on a BRUKER AVANCE II 400 NMR Spectrometer using tetramethylsilane (TMS) as internal standard. The progress of the reaction was monitored by thin layer chromatography (TLC) using silica gel G (Merck).

4.2. General Method for the Synthesis of 5-Arylidene Rhodanine and 2,4-Thiazolidinedione (3a–n). A mixture-nitrone (10 mmol) 1, rhodanine or 2,4-thiazolidinedione (10 mmol) 2, and polyethylene glycol (5 mL) was stirred at 80°C temperature for appropriate time (see Table 1). Reaction progress was monitored via TLC. After reaction completion, crude product was precipitated out on cooling. Obtained product was filtered, dried, and for further purification recrystallized from ethanol-DMF.

4.3. Spectral Data of Representative Compounds. (5Z)-5-Benzylidene-1,3-thiazolidine-2,4-dione (3a): IR (KBr) cm⁻¹: 3155 (NH), 3049, 879 (CH; aromatic), 2868 (CH; aliphatic), 1739, 1691 (C=O). 1H NMR (300 MHz, DMSO-d₆) δH: 8.27 (1H, s, NH), 7.86 (1H, s, CH), 7.26 (5H, m, aromatic protons). MS m/z (%): 206 (M + 1).

(5Z)-5-(4-Methylbenzylidene)-1,3-thiazolidine-2,4-dione (3b): IR (KBr) cm⁻¹: 3155 (NH), 3049, 879 (CH; aromatic), 2868 (CH; aliphatic), 1739, 1691 (C=O). 1H NMR (300 MHz, DMSO-d₆) δH: 8.32 (1H, s, NH), 7.86 (1H, s, CH), 7.26 (5H, m, aromatic protons). MS m/z (%): 206 (M + 1).

Acknowledgment

The authors are thankful to Sophisticated Analytical Instrument Facility Central Instrument Laboratory, Panjab University, Chandigarh, for spectral analysis.

References

[1] M. Yu, M. Kanji, I. Hitoshi, H. Chitoshi, O. Satoru, and S. Takashi, “Studies on antidiabetic agents—10. Synthesis and biological activities of pioglitazone and related compounds,” Chemical & Pharmaceutical Bulletin, vol. 39, no. 6, pp. 1440–1445, 1991.

[2] J. H. Ahn, S. J. Kim, W. S. Park et al., “Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 11, pp. 2996–2999, 2006.

[3] M. Sortino, P. Delgado, S. Juárez et al., “Synthesis and antifungal activity of (Z)-5-arylidenerhodanines,” Bioorganic & Medicinal Chemistry, vol. 15, no. 1, pp. 484–494, 2007.

[4] T. S. Wan, L. L. Cheng, L. Y. Su, P. L. Siew, and M. S. Mui, “Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor,” Bioorganic & Medicinal Chemistry Letters, vol. 11, pp. 91–94, 2001.

[5] M. M. Sim, S. B. Ng, A. D. Buss, S. C. Crasta, K. L. Goh, and S. K. Lee, “Benzyldiene rhodanines as novel inhibitors of UDP-N-acetylglucosamine-1-carboxylic acid: N-acetylmuramate-L-asparagine ligase,” Bioorganic & Medicinal Chemistry Letters, vol. 12, no. 4, pp. 697–699, 2002.

[6] R. MacCari, A. D. Corso, M. Giglio, R. Moschini, U. Mura, and R. Ottan, “In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 1, pp. 200–203, 2011.

[7] E. B. Grant, D. Guiadeen, E. Z. Baum et al., “The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors,”
Bioorganic & Medicinal Chemistry Letters, vol. 10, no. 19, pp. 2179–2182, 2000.

S. C. Neil, O. Christine, and P. Marina, "Rhodanine derivatives as inhibitors of JSP-1," Bioorganic & Medicinal Chemistry Letters, vol. 15, pp. 3374–3379, 2005.

E. Tang, G. Yang, and J. Yin, "Studies on the synthesis of 5-(p-aminobenzylidene)-rhodanine and its properties," Spectrochimica Acta Part A, vol. 59, no. 3, pp. 651–656, 2003.

D. A. Heerding, L. T. Christmann, T. J. Clark et al., "New benzylidenethiazolidinediones as antibacterial agents," Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 21, pp. 3771–3773, 2003.

Z. Jian-Feng, Z. Feng-Xia, S. Yuan-Zhi, and Z. Yu-Lan, "Synthesis of 5-arylalkylidene rhodanine derivatives catalyzed by tetrabutylammonium bromide in water under microwave irradiation," Archive for Organic Chemistry, vol. 14, pp. 175–180, 2006.

C. L. Lee and M. M. Sim, "Solid-phase combinatorial synthesis of 5-arylylidene rhodanine, Tetrahedron Letters, vol. 41, no. 30, pp. 5729–5732, 2000.

B. C. C. Cantello, M. A. Cawthorne, G. P. Cottam et al., "[(ω-(Heterocyclylamino)alkyl)benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents," Journal of Medicinal Chemistry, vol. 37, no. 23, pp. 3977–3985, 1994.

I. M. Labouta, H. M. Salama, N. H. Eshba, O. Kader, and E. El-chrbini, "Potential anti-microbial: synthases and in vitro anti-microbial evaluation of some 5-aryalo-thiazolidines and related compounds," European Journal of Medicinal Chemistry, vol. 22, pp. 485–489, 1987.

R. Ottanà, R. MacCari, M. L. Barreca et al., "5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents," Bioorganic and Medicinal Chemistry, vol. 13, no. 13, pp. 4243–4252, 2005.

J. D. Peuler, S. M. Phare, A. R. Iannucci, and M. J. Hodorek, "Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation," American Journal of Hypertension, vol. 9, pp. 188–192, 1996.

G. Bruno, L. Costantino, C. Curinga et al., "Synthesis and aldose reductase inhibitory activity of 5-aryliden-2,4-thiazolidinediones," Bioorganic and Medicinal Chemistry, vol. 10, no. 4, pp. 1077–1084, 2002.

Y. Wu, S. Karna, C. H. Choi et al., "Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors," Journal of Medicinal Chemistry, vol. 54, no. 14, pp. 5260–5264, 2011.

Z. Nace, T. Tihomir, S. Roman et al., "Discovery of novel 5-benzylidenethodanine and 5-benzylidenethiazolidine-2, 4-dione inhibitors of MurD ligase," Journal of Medicinal Chemistry, vol. 53, no. 18, pp. 6584–6594, 2010.

M. A. Ibrahim, M. A. M. Abdel-Hamed, and N. M. El-Gohary, "A new approach for the synthesis of bioactive heteroaryl thiazolidine-2,4-diones," Journal of the Brazilian Chemical Society, vol. 22, no. 6, pp. 1130–1139, 2011.

S. Mahalle, D. Ligampalle, and R. Mane, "Microwave-assisted synthesis of some 2,4-thiazolidinedione derivatives," Heterocycles, vol. 20, no. 3, pp. 151–156, 2009.

D. H. Yang, B. Y. Yang, Z. C. Chen, and S. Y. Chen, "A convenient synthesis of 5-arylidenethiazolidine-2,4-diones on potassium fluoride-aluminium oxide," Organic Preparations and Procedures International, vol. 38, no. 1, pp. 81–85, 2006.